港股異動丨香港醫思醫療漲近6% 與德視佳擬成立合資企業發展眼科服務
格隆匯10月31日丨香港醫思醫療(2138.HK)漲近6%,報5.83港元,成交1023萬港元,總市值57.44億港元。

香港醫思醫療集團今日早間公佈,與德視佳集團(1846.HK) 於2019年10月30日訂立了一份不具約束力的備忘錄,雙方擬成立一家合資公司發展眼科服務及相關業務。本集團與德視佳集團將各持擬合資企業50%權益。根據備忘錄,醫思醫療集團與德視佳集團將探索共同發展中國眼科業務,並計劃於目前已有業務的地區,包括廣州及深圳啟動。德視佳集團將主要負責擬合資企業的醫療事項,醫思醫療集團則主要負責香港的營銷及招募。擬合資企業的條款仍在磋商中,實際協議預計於2019年12月31日或以前簽署。 銀河聯昌證券發表最新研究報告,維持香港醫思醫療增持評級,基於2020歷年20倍市盈率計算,目標價8.14港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.